Evidence map›Paper›PMID 34390420›Full record

ArticleNanoscale research letters2021

Facile Fabrication of BiF

Jun Xie, Zonglang Zhou, Sihan Ma, Xian Luo, Jiajing Liu, Shengyu Wang, Yuqiang Chen, Jianghua Yan, Fanghong Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Human serum albumin-based KBiFJournal of nanobiotechnology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun Xie *Cancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China.
Zonglang Zhou *The 174th Clinical College of People's Liberation Army, Anhui Medical University, Hefei, 230032, China.
Sihan MaCollege of Energy, Xiamen University, Xiamen, 361102, China.
Xian LuoCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China.
Jiajing LiuCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China.
Shengyu WangCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China.
Yuqiang ChenCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China. chenyq707@163.com.
Jianghua YanCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China. jhyan@xmu.edu.cn.
Fanghong LuoCancer Research Center, Medical College, Xiamen University, Xiamen, 361102, China. luofanghong@xmu.edu.cn.

Funding

Fujian Provincial Department of Science and Technology 2018R1036-1, 2019R1001-2 and 2020R1001001National Natural Science Foundation of China 81773770
6 · The paper itself

Abstract

X-ray computed tomography (CT) has been widely used in clinical practice, and contrast agents such as Iohexol are often used to enhance the contrast of CT imaging between normal and diseased tissue. However, such contrast agents can have some toxicity. Thus, new CT contrast agents are urgently needed. Owing to the high atomic number (Z = 83), low cost, good biological safety, and great X-ray attenuation property (5.74 cm

Indexed as

BiF3: Ln@PVP nanoparticlesComputed tomographyContrast agentsFacile synthesized strategyGastrointestinal tract imaging

Identifiers

PMID34390420
PMCPMC8364619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.